Literature DB >> 22189945

Hydroxyproline metabolism in mouse models of primary hyperoxaluria.

John Knight1, Ross P Holmes, Scott D Cramer, Tatsuya Takayama, Eduardo Salido.   

Abstract

Primary hyperoxaluria type 1 (PH1) and type 2 (PH2) are rare genetic diseases that result from deficiencies in glyoxylate metabolism. The increased oxalate synthesis that occurs can lead to kidney stone formation, deposition of calcium oxalate in the kidney and other tissues, and renal failure. Hydroxyproline (Hyp) catabolism, which occurs mainly in the liver and kidney, is a prominent source of glyoxylate and could account for a significant portion of the oxalate produced in PH. To determine the sensitivity of mouse models of PH1 and PH2 to Hyp-derived oxalate, animals were fed diets containing 1% Hyp. Urinary excretions of glycolate and oxalate were used to monitor Hyp catabolism and the kidneys were examined to assess pathological changes. Both strains of knockout (KO) mice excreted more oxalate than wild-type (WT) animals with Hyp feeding. After 4 wk of Hyp feeding, all mice deficient in glyoxylate reductase/hydroxypyruvate reductase (GRHPR KO) developed severe nephrocalcinosis in contrast to animals deficient in alanine-glyoxylate aminotransferase (AGXT KO) where nephrocalcinosis was milder and with a lower frequency. Plasma cystatin C measurements over 4-wk Hyp feeding indicated no significant loss of renal function in WT and AGXT KO animals, and significant and severe loss of renal function in GRHPR KO animals after 2 and 4 wk, respectively. These data suggest that GRHPR activity may be vital in the kidney for limiting the conversion of Hyp-derived glyoxylate to oxalate. As Hyp catabolism may make a major contribution to the oxalate produced in PH patients, Hyp feeding in these mouse models should be useful in understanding the mechanisms associated with calcium oxalate deposition in the kidney.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189945      PMCID: PMC3311317          DOI: 10.1152/ajprenal.00473.2011

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  16 in total

1.  Mitochondrial hydroxyproline metabolism: implications for primary hyperoxaluria.

Authors:  John Knight; Ross P Holmes
Journal:  Am J Nephrol       Date:  2005-04-21       Impact factor: 3.754

2.  Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline.

Authors:  S R Khan; P A Glenton; K J Byer
Journal:  Kidney Int       Date:  2006-07-19       Impact factor: 10.612

3.  Hydroxyproline ingestion and urinary oxalate and glycolate excretion.

Authors:  J Knight; J Jiang; D G Assimos; R P Holmes
Journal:  Kidney Int       Date:  2006-10-04       Impact factor: 10.612

4.  The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II.

Authors:  S D Cramer; P M Ferree; K Lin; D S Milliner; R P Holmes
Journal:  Hum Mol Genet       Date:  1999-10       Impact factor: 6.150

5.  Serum oxalate in human beings and rats as determined with the use of ion chromatography.

Authors:  Anastasia H Harris; Robert W Freel; Marguerite Hatch
Journal:  J Lab Clin Med       Date:  2004-07

6.  A porcine model of calcium oxalate kidney stone disease.

Authors:  Neil S Mandel; James D Henderson; Linda Y Hung; David F Wille; John H Wiessner
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

Review 7.  Glyoxylate synthesis, and its modulation and influence on oxalate synthesis.

Authors:  R P Holmes; D G Assimos
Journal:  J Urol       Date:  1998-11       Impact factor: 7.450

8.  Hydroxyproline-induced hyperoxaluria using acidified and traditional diets in the porcine model.

Authors:  Daniel M Kaplon; Kristina L Penniston; Camille Darriet; Thomas D Crenshaw; Stephen Y Nakada
Journal:  J Endourol       Date:  2010-03       Impact factor: 2.942

Review 9.  Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation.

Authors:  P J Thornalley
Journal:  Biochem Soc Trans       Date:  2003-12       Impact factor: 5.407

10.  Dietary soy beta-conglycinin (7S globulin) inhibits atherosclerosis in mice.

Authors:  Michael R Adams; Deborah L Golden; Adrian A Franke; Susan M Potter; Houston S Smith; Mary S Anthony
Journal:  J Nutr       Date:  2004-03       Impact factor: 4.798

View more
  16 in total

1.  An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.

Authors:  Abigail Liebow; Xingsheng Li; Timothy Racie; Julia Hettinger; Brian R Bettencourt; Nader Najafian; Patrick Haslett; Kevin Fitzgerald; Ross P Holmes; David Erbe; William Querbes; John Knight
Journal:  J Am Soc Nephrol       Date:  2016-07-18       Impact factor: 10.121

2.  Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.

Authors:  Xingsheng Li; John Knight; Sonia Fargue; Brianna Buchalski; Zhengrong Guan; Edward W Inscho; Abigail Liebow; Kevin Fitzgerald; William Querbes; W Todd Lowther; Ross P Holmes
Journal:  Biochim Biophys Acta       Date:  2015-12-02

3.  Metabolic profile and impact of diet in patients with primary hyperoxaluria.

Authors:  Roswitha Siener; Bernd Hoppe; Patricia Löhr; Stefan C Müller; Stefan Latz
Journal:  Int Urol Nephrol       Date:  2018-07-23       Impact factor: 2.370

Review 4.  Experimental models of renal calcium stones in rodents.

Authors:  Héloïse Bilbault; Jean-Philippe Haymann
Journal:  World J Nephrol       Date:  2016-03-06

5.  Combined Liver-Kidney Transplantation for Primary Hyperoxaluria Type 2: A Case Report.

Authors:  T Dhondup; E C Lorenz; D S Milliner; J C Lieske
Journal:  Am J Transplant       Date:  2017-08-14       Impact factor: 8.086

6.  Genetic cause and prevalence of hydroxyprolinemia.

Authors:  Christian Staufner; Tobias B Haack; Patrik Feyh; Gwendolyn Gramer; Deepthi Ediga Raga; Caterina Terrile; Sven Sauer; Jürgen G Okun; Junmin Fang-Hoffmann; Ertan Mayatepek; Holger Prokisch; Georg F Hoffmann; Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2016-05-02       Impact factor: 4.982

7.  Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria.

Authors:  Sonia Fargue; Dawn S Milliner; John Knight; Julie B Olson; W Todd Lowther; Ross P Holmes
Journal:  J Am Soc Nephrol       Date:  2018-03-27       Impact factor: 10.121

Review 8.  Ascorbic acid intake and oxalate synthesis.

Authors:  John Knight; Kumudu Madduma-Liyanage; James A Mobley; Dean G Assimos; Ross P Holmes
Journal:  Urolithiasis       Date:  2016-03-22       Impact factor: 3.436

9.  The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.

Authors:  Brianna Buchalski; Kyle D Wood; Anil Challa; Sonia Fargue; Ross P Holmes; W Todd Lowther; John Knight
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-12-07       Impact factor: 5.187

10.  Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity.

Authors:  Kyle D Wood; Ross P Holmes; David Erbe; Abigail Liebow; Sonia Fargue; John Knight
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-05-02       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.